相关实验视频
Updated: Jun 19, 2026

07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 16, 2010
克桑丁氧化酶抑制可以逆转重度吸烟者的内皮功能障碍
Sashi Guthikonda1, Christine Sinkey, Therese Barenz
1Department of Internal Medicine and General Clinical Research Center, University of Iowa Carver College of Medicine, Iowa City 52242, USA.
Circulation
|January 29, 2003
概括
吸烟会导致内皮功能障碍,但丁氧化酶抑制剂allopurinol在吸烟者中迅速扭转了这种情况. 这些发现表明,丁氧化酶在吸烟引起的内皮功能障碍中起着关键作用.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 吸烟是内皮功能障碍的已知原因,可能由增加的氧化应激引起.
- 酶丁氧化酶产生氧化自由基,使其与吸烟相关的血管损伤有关.
研究的目的:
- 调查香烟吸烟引起的内皮功能障碍中桑丁氧化酶的作用.
- 为了确定是否用艾洛普林醇抑制丁氧化酶可以逆转吸烟者的内皮功能障碍.
主要方法:
- 一个随机的,双相交叉研究,涉及14名吸烟者和14名非吸烟者.
- 单次口服600毫克的阿洛普林醇剂量用于抑制丁氧化酶.
- 评估前臂血流对乙胆,布拉迪基宁和尼特胺的反应;用L-NMMA抑制氧化合成酶.
主要成果:
- 与对照组相比,吸烟者表现出乙胆诱导的血管扩张显著受损 (P=0.009).
- 在吸烟者中,阿洛普林醇的使用显著改善了内皮功能 (乙胆反应增加了463+/-78%,P=0.001).
- 吸烟者服用阿洛普醇 (P=0.06) 时,布拉迪基宁的反应也得到改善,而尼特和L-NMMA的反应保持不变.
结论:
- 口服的阿洛普醇迅速扭转了阻力血管中吸烟引起的内皮功能障碍.
- 这些结果强烈表明,丁氧化酶是吸烟引起的内皮功能障碍的重要贡献者.
相关概念视频
Antiasthma Drugs: Methylxanthines
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.

